ClinicalTrials.gg
Active, not recruitingNCT05688475Updated Nov 5, 2026

A Rollover Study of CC-122

A Phase 1 interventional study of CC-122 and Dexamethasone in Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb. Active, not recruiting at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Non-Hodgkin · Bristol-Myers Squibb.

Planned enrollment
40th of 46
12 · median 58
Started
2023
with 2 others
Phase 1
18 of 50
none open now
Registered
47th of 50
by date

Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 40th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 in phase 1, and was the 47th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001 [NCT02031419], and CC-122-NHL-001 [NCT02417285]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.

03

Conditions studied

  • Non-Hodgkin Lymphoma

Keywords

  • CC-122
  • Avadomide
  • BMS-986381
  • Non-Hodgkin Lymphoma
  • Diffuse large B cell lymphoma
  • Follicular lymphoma
  • Chronic lymphocytic leukemia
  • Multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant who is currently receiving CC-122 on another CC-122 clinical trial that has met its primary and secondary endpoints.
  • Participant who has participated in previous CC-122 protocol (including CC-122-ST-001 [NCT01421524], CC-122-ST-002 [NCT02509039], CC-122-DBCL-001 [NCT02031419], and CC-122-NHL-001 [NCT02417285]), and is deemed by the investigator to be deriving benefit from CC-122 as defined by the previous protocol.
  • Participant who is able to tolerate study therapy and has not yet experienced progressive disease or any treatment discontinuation criteria of the Parent Study.

Key Exclusion Criteria:

  • Participant is not eligible for CC-122 treatment as per the Parent Study.
  • Participants not receiving clinical benefit as assessed by the investigator. Any clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the participant.
  • Women who are breastfeeding.

Note: Other protocol-defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    CC-122 and Dexamethasone

    Drug: CC-122 · Drug: Dexamethasone

Interventions

  • DrugCC-122

    Specified dose on specified days

    Also known as: Avadomide, BMS-986381

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with serious adverse events (SAEs) for participants who received at least 1 dose of CC-122

    Time frame: Up to approximately 3 years

  2. Number of deaths for participants who received at least 1 dose of CC-122

    Time frame: Up to approximately 3 years

07

Study locations

7 sites
  • Local Institution - 100
    New York, New York 10065, United States
  • Local Institution - 101
    Nashville, Tennessee 37203, United States
  • Local Institution - 102
    Madison, Wisconsin 53792, United States
  • Local Institution - 300
    Bordeaux, 33076, France
  • Local Institution - 301
    Marseille, 13273, France
  • Local Institution - 500
    Koto-ku, Tokyo 1358550, Japan
  • Local Institution - 400
    Amsterdam, 1105, Netherlands
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 43 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 43 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 18, 2023
StartActual
Apr 11, 2023
Primary completionEst.
Nov 30, 2026was Oct 2026
CompletionEst.
Nov 30, 2026was Oct 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Nov 30, 2026
Nov 5, 2026
Study completion
Oct 31, 2026→Nov 30, 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Oct 31, 2026→Nov 30, 2026
    Study completion Oct 31, 2026→Nov 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05688475
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Apr 11, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avadomide

Start the discussion